Scientists test supercharged immune cells against tough cancers
NCT ID NCT02948426
Summary
This early-stage study tested a new treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned or stopped responding to standard therapies. Researchers collected a patient's own immune cells (monocytes), activated them with two drugs (Sylatron and Actimmune), and then infused them back into the abdomen. The main goal was to find the safest dose and see if this approach could help shrink tumors or slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.